Innovative Cardiovascular Solutions is a Kalamazoo, Mich.-based clinical-stage company led by co-founder and CEO R. Kevin Plemmons that completed a Series C financing raising $8M. The company develops the Emblok™ Embolic Protection System for use in Transcatheter Aortic Valve Replacement (TAVR) and other structural heart procedures where embolic protection is required. Emblok is designed to provide complete circumferential aortic collection while protecting the cerebral, abdominal and peripheral vasculature from liberated embolic debris. The system features an integrated 4 Fr radiopaque pigtail catheter that provides constant visualization and eliminates the need for unnecessary dye injections to verify positioning; the entire system is 11 Fr and allows deployment of two devices through a single femoral puncture. Emblok is available for investigational use only and is not approved for sale. The company intends to use the funds to conduct clinical trials in the U.S. and Europe and to support manufacturing and operational activities. Innovative Cardiovascular Solutions (ICS) is a clinical-stage company based in Kalamazoo, MI, developing the EMBLOK Embolic Protection System for Transcatheter Aortic Valve Replacement (TAVR) and other structural heart procedures. The EMBLOK system is designed to offer complete circumferential aortic collection while protecting the cerebral, abdominal and peripheral vasculature from liberated embolic debris. It includes an integrated 4 Fr radiopaque pigtail catheter to provide constant visualization and eliminate the need for unnecessary dye injections to verify positioning. The entire system is 11 Fr and permits deployment of two devices (an embolic filter and pigtail catheter) through a single femoral puncture site. ICS plans to use the recent proceeds to continue device development and to initiate a 510(k) clinical study in the U.S. The company is led by co-founder and CEO R. Kevin Plemmons.

Total raised

$13M

Funding rounds

2

Latest round

Series C

Latest activity

Dec 2018